An effective nurse navigator approach involves removing barriers to good care, such as differences in health care delivery systems, poor communication, and financial impediments.
A lack of needed transfusion services was cited as why many hematologic oncologists are less likely to refer their patients with blood cancers to home hospice care.
Recent study results demonstrate that recombinant IL-11 with glucocorticoids is a safe and effective treatment for idiopathic thrombocytopenic purpura (ITP) in adults.
Approximately 40% of ITP cases are caused by gram-negative H pylori infection; therefore, researchers sought to determine the effectiveness of infection eradication on platelet count in these patients.
A nurse-led team developed a tracking tool that created a vaccination schedule from transplant date forward for autologous hematopoietic stem cell transplant recipients.
An international team developed an approach to hematopoietic stem cell transplantation that prevents GVHD while preserving the benefits of the therapy.
A case of simultaneous PAP and MPN diagnoses demonstrate the importance of evaluating for GM-CSF autoantibodies to distinguish autoimmune and secondary forms of PAP.
MIT team develops simple, less painful diagnostic test for multiple myeloma using microfluidic chip and conventional blood sample.
In this review of the role of bortezomib in the treatment of multiple myeloma, the researchers explain what nurses need to watch for in patients taking this drug.
Research on the transformation of MDS to AML identifies a protein whose deletion is a potential tumor suppressor that would block this disease progression.
BRAF other MAPK pathway gene mutations associated with Erdheim-Chester disease reveal that ECD is a neoplastic disease.
Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.
A novel agent, letermovir, reduced incidence of CMV in patients undergoing stem cell transplantation for hematologic malignancies.
A hematologic multidisciplinary oral chemotherapy clinic established at a community hospital identified adverse events early and reduced ED visits.
Carfilzomib significantly prolonged overall survival compared with bortezomib in patients with relapsed or refractory multiple myeloma.
Younger and usual adult body mass index (BMI) may be linked to increased risk for developing multiple myeloma, research indicates.
Lenalidomide maintenance appears efficacious for relapsed diffuse large B cell lymphoma.
Blood test combined with medical status information predicts stem cell transplant success in patients with MDS.
Patients who were surveyed reported that the benefits of treatment with BV outweighed its risks.
PD-1 blockade with pembrolizumab was active and induced durable responses in patients with natural killer (NK)/T-cell lymphoma failing L-asparaginase.
Bendamustine, bortezomib, and dexamethasone is efficacious and tolerable as first-line therapy for patients with myeloma ineligible to receive high-dose therapy.
Ibrutinib, idelalisib, ponatinib, and ruxolitinib are each associated with a variety of potential adverse effects and oncology nurses must be aware of these to successfully monitor for them.
Frontline Bosutinib Superior to Imatinib for Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic PhaseFebruary 09, 2017
Bosutinib outperformed imatinib as first-line therapy for patients with Ph+ chronic myeloid leukemia in chronic phase, according to trial data.
In this study, researchers measured the psychological manifestations among patients with BCR-ABL-negative MPNs to determine the effects of anxiety, distress, and depression on symptom burden in this patient population.
Results are presented from the phase 3 ENDEAVOR trial, which demonstrated the effect of carfilzomib plus dexamethasone (Kd) vs bortezomib plus dexamathasone (Vd) on risk of disease progression or death in patients with relapsed or refractory multiple myeloma.
Azathioprine for the treatment of autoimmune disorders is significantly associated with an increased risk of acute myeloid leukemia and myelodysplastic syndromes.
A pooled analysis confirms the role of upfront autologous HCT as the standard approach for all young patients with multiple myeloma.
Ibrutinib appears to be superior first kinase inhibitor for individuals with chronic lymphocytic leukemia, according to a recent real-world study.
In this study, maintenance therapy with bortezomib plus thalidomide was compared with thalidomide alone or interferon alfa-2b alone in patients with newly diagnosed symptomatic multiple myeloma. Study findings demonstrate an impact on progression-free survival.
- Immunotherapy May Benefit Some Patients with Papillary Thyroid Carcinoma
- Screening Recommendations for Children with Common Cancer Predisposition Syndromes
- Significance of Prostate Cancer Treatment-Related Factors Differ in Black, White Men
- New Study Questions Standard Dosage for Treating Metastatic Non-Small Cell Lung Cancer
- Superior Tolerability, Efficacy With Alectinib in Treatment-Naïve ALK-poistive NSCLC
- Survivorship Care Plans: Providing A Blueprint for Health Care After Cancer
- Cancer Recurrence Fear Reduced by Novel Psychological Intervention
- Multifaceted Role of the Nurse Navigator Includes Palliative, Supportive Care
- Patient Navigators Found to Boost Lung Cancer Screening Rates
- Lack of Transfusion Services a Barrier to Hospice Care for Patients With Blood Cancers
- Breast Cancer Overdiagnosis Also a Result of Screening Mammography Programs
- Use of Aspirin, NSAIDs Correlates with Improved Overall Survival in Colorectal Cancer
- Cancer Risk Not Increased by Childhood Exposure to Diagnostic Radiation
- Aspirin Use May Lower Breast Cancer Risk in Women with Diabetes
- Ethnic Differences, Cultural Barriers Negatively Impact Mammography Follow-up Among Asian Ethnic Groups
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|